What's Happening?
The Community Oncology Alliance (COA) is urging the Centers for Medicare & Medicaid Services (CMS) and Congress to address the impact of Medicare's drug price negotiation program on physician-administered Part B drugs. Starting in 2028, reimbursement
for negotiated drugs will shift from the current Average Sales Price (ASP) plus 6% to a Maximum Fair Price (MFP), which is anticipated to be significantly lower than ASP. Avalere Health projects this change could lead to an industry-wide erosion of up to 19% in ASP by 2032, potentially resulting in over $25 billion in lost add-on payments. Specifically, oncology and hematology drugs could experience a 39% to 64% drop in add-on payments, amounting to a potential $12 billion to $19 billion hit across just three drugs over five years. COA Executive Director Ted Okon, MBA, stated that this is not a minor reimbursement change and could force practices to cease providing certain therapies, consolidate, or close. The COA is advocating for HR 4299 as a legislative solution.
Why It's Important?
This development is critical for the U.S. healthcare system, particularly for cancer patients and community oncology practices. A significant reduction in reimbursement for physician-administered Part B drugs could destabilize community oncology centers, which provide a substantial portion of cancer care in the U.S. If these practices are forced to close or limit services, patients, especially those in rural or underserved areas, may face reduced access to essential cancer treatments. The financial strain on practices could also hinder their ability to invest in new technologies or maintain staffing levels, potentially compromising the quality of care. Furthermore, the shift to MFP could impact the pharmaceutical industry's incentives for research and development in oncology, as the profitability of new cancer drugs might decrease. This situation highlights a tension between efforts to control drug costs and the need to ensure the viability of healthcare providers and access to life-saving treatments.
What's Next?
The Community Oncology Alliance will continue to lobby CMS and Congress to modify the application of the Medicare drug price negotiation program to physician-administered Part B drugs. The proposed legislative fix, HR 4299, will likely be a focal point of these advocacy efforts. Stakeholders, including pharmaceutical companies, patient advocacy groups, and healthcare providers, will closely monitor the legislative process and any potential adjustments from CMS. Oncology practices will need to assess their financial models and operational strategies in anticipation of the 2028 changes, potentially exploring options for consolidation or changes in service offerings. The broader pharmaceutical industry will also be watching to see if these reimbursement changes influence future drug development and pricing strategies, particularly for high-cost specialty drugs covered under Medicare Part B.
Beyond the Headlines
The debate over Medicare drug price negotiation for Part B drugs extends beyond immediate financial impacts, touching upon fundamental questions of healthcare access, innovation, and the role of government in drug pricing. The potential closure of community oncology practices could exacerbate existing healthcare disparities, as these centers often serve vulnerable populations. This situation also raises ethical considerations regarding the balance between cost containment and ensuring patient access to cutting-edge treatments. The long-term implications could include a shift in the landscape of cancer care delivery, potentially favoring larger hospital systems over independent community practices. Moreover, the precedent set by these negotiations could influence future policies for other high-cost medical treatments, shaping the future of pharmaceutical innovation and healthcare economics in the U.S.
